Environmentalists have called for integrated approach in management of e-waste and other consumer products containing Polybrominated Diphenyl Ethers, ...
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2L4EBCQ
Environmentalists have called for integrated approach in management of e-waste and other consumer products containing Polybrominated Diphenyl Ethers, ...
Environmentalists have called for integrated approach in management of e-waste and other consumer products containing Polybrominated Diphenyl Ethers, ...
The relationship between smoking, household pollution, dual exposure and severity of asthma in adults has not been sufficiently studied. We examined and compared the effects of cigarette smoking, domestic wood burning pollution and dual exposure (tobacco and wood burning) upon asthma severity in adults.
This was a cross-sectional study performed with 452 individuals with mild to moderate asthma and 544 patients with severe asthma (previously untreated). Smoking and exposure to wood smoke were identified and quantified through questionnaires to evaluate current and/or previous exposure; objective determination of cigarette exposure was obtained through the measurement of urinary cotinine. Asthma control was evaluated through Asthma Control Questionnaire; and severity was classified according to the Global Initiative for Asthma criteria. Subjects were grouped according to exposure type into 4 groups: smokers, household pollution, dual-exposure and no-exposure. Chi square, Mann–Whitney, and Kruskal–Wallis tests were used for comparisons between groups.
Out of 996 included individuals, 78 (7.8%) were exposed to cigarette smoking alone, 358 (35.9%) to household pollution alone, 155 (15.6%) to the two exposures combined and 405 (40.7%) were not exposed. Compared to unexposed individuals, exposure to household pollution resulted in poorer asthma control, higher proportion of severe asthma, and worse indicators of lung function. The double-exposed individuals were worse off in all the evaluated parameters, and they were significantly worse than subjects with single exposure to household air pollution in relation to asthma severity and lung function. These subjects were predominantly females, older, with longer residence time in rural areas, lower income and lower schooling levels. Multivariate analysis showed that exposure to household pollution and double exposure were predictive factors associated with lack of control and increased severity of asthma.
Exposure to household pollution is associated with poorer control, greater severity, and poorer pulmonary function; double-exposed individuals have a greater risk of severe asthma and decreased lung function than those exposed only to household pollution.
The relationship between smoking, household pollution, dual exposure and severity of asthma in adults has not been sufficiently studied. We examined and compared the effects of cigarette smoking, domestic wood burning pollution and dual exposure (tobacco and wood burning) upon asthma severity in adults.
This was a cross-sectional study performed with 452 individuals with mild to moderate asthma and 544 patients with severe asthma (previously untreated). Smoking and exposure to wood smoke were identified and quantified through questionnaires to evaluate current and/or previous exposure; objective determination of cigarette exposure was obtained through the measurement of urinary cotinine. Asthma control was evaluated through Asthma Control Questionnaire; and severity was classified according to the Global Initiative for Asthma criteria. Subjects were grouped according to exposure type into 4 groups: smokers, household pollution, dual-exposure and no-exposure. Chi square, Mann–Whitney, and Kruskal–Wallis tests were used for comparisons between groups.
Out of 996 included individuals, 78 (7.8%) were exposed to cigarette smoking alone, 358 (35.9%) to household pollution alone, 155 (15.6%) to the two exposures combined and 405 (40.7%) were not exposed. Compared to unexposed individuals, exposure to household pollution resulted in poorer asthma control, higher proportion of severe asthma, and worse indicators of lung function. The double-exposed individuals were worse off in all the evaluated parameters, and they were significantly worse than subjects with single exposure to household air pollution in relation to asthma severity and lung function. These subjects were predominantly females, older, with longer residence time in rural areas, lower income and lower schooling levels. Multivariate analysis showed that exposure to household pollution and double exposure were predictive factors associated with lack of control and increased severity of asthma.
Exposure to household pollution is associated with poorer control, greater severity, and poorer pulmonary function; double-exposed individuals have a greater risk of severe asthma and decreased lung function than those exposed only to household pollution.
Dear Mr Fishman and Dr Cullen,. Thank you for writing this exhaustive article on sudden hearing loss which will be a useful guide to primary care, emergency ...
Dear Mr Fishman and Dr Cullen,. Thank you for writing this exhaustive article on sudden hearing loss which will be a useful guide to primary care, emergency ...
Assessments of age-specific mortality and life expectancy have been done by the UN Population Division, Department of Economics and Social Affairs (UNPOP) ...
Assessments of age-specific mortality and life expectancy have been done by the UN Population Division, Department of Economics and Social Affairs (UNPOP) ...

A third-quarter earnings surprise and a European approval gave the stock some lift.

A third-quarter earnings surprise and a European approval gave the stock some lift.
Affordability of recently licensed cancer medicines, use of English, French, and Australian health technology assessments (HTAs) to analyze all new cancer ...
![]()
Response Genetics (OTCMKTS:RGDXQ) and IDEXX Laboratories (NASDAQ:IDXX) are both medical companies, but which is the better stock? We will compare ...
Affordability of recently licensed cancer medicines, use of English, French, and Australian health technology assessments (HTAs) to analyze all new cancer ...
![]()
Response Genetics (OTCMKTS:RGDXQ) and IDEXX Laboratories (NASDAQ:IDXX) are both medical companies, but which is the better stock? We will compare ...
Interpace Diagnostics Group (NASDAQ:IDXG) has been given a $4.00 price target by research analysts at Maxim Group in a research note issued on ...
Interpace Diagnostics Group (NASDAQ:IDXG) has been given a $4.00 price target by research analysts at Maxim Group in a research note issued on ...
Panaji: As many as 280 patients have registered at the cancer out-patient department (OPD) at Goa Medical College, Bambolim, since it started in the l.
Health insurer Aetna denied proton therapy because it was 'experimental.' This jury verdict raises the possibility that other denial-of-care suits will follow.
Panaji: As many as 280 patients have registered at the cancer out-patient department (OPD) at Goa Medical College, Bambolim, since it started in the l.
Health insurer Aetna denied proton therapy because it was 'experimental.' This jury verdict raises the possibility that other denial-of-care suits will follow.
More than a third of people in the SAR binge drink, according to a survey of 1,119 people by the Hong Kong Anti-Cancer Society. About 69 percent started ...

Head And Neck Cancer Treatment Market is analysed on the basis of: Business segments, Organizational developments, Geographical focus, Segment focus, ...
More than a third of people in the SAR binge drink, according to a survey of 1,119 people by the Hong Kong Anti-Cancer Society. About 69 percent started ...

Head And Neck Cancer Treatment Market is analysed on the basis of: Business segments, Organizational developments, Geographical focus, Segment focus, ...
CONCLUSIONS: In most cases, mast cell mediator-induced and bradykinin-mediated forms of angioedema are readily classified clinically and/or by laboratory tests. In very rare cases, however, the cause and mediators of angioedema remain unknown. PMID: 30506093 [PubMed - as supplied by publisher] (Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
CONCLUSIONS: In most cases, mast cell mediator-induced and bradykinin-mediated forms of angioedema are readily classified clinically and/or by laboratory tests. In very rare cases, however, the cause and mediators of angioedema remain unknown. PMID: 30506093 [PubMed - as supplied by publisher] (Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Results of the Phase III EAGLE study leave Merck's Keytruda and Bristol's Opdivo as the dominant players in the space of HNSCC after progression on ...

Results of the Phase III EAGLE study leave Merck's Keytruda and Bristol's Opdivo as the dominant players in the space of HNSCC after progression on ...

Oberweis Asset Management Inc increased New Jersey Res Corp. (NJR) stake by 78.17% reported in 2018Q2 SEC filing. Oberweis Asset Management Inc ...

Oberweis Asset Management Inc increased New Jersey Res Corp. (NJR) stake by 78.17% reported in 2018Q2 SEC filing. Oberweis Asset Management Inc ...
Thursday, Nov. 15, is the American Cancer Society's Great American Smokeout and Essentia Health wants to help smokers quit for good for better health.
Thursday, Nov. 15, is the American Cancer Society's Great American Smokeout and Essentia Health wants to help smokers quit for good for better health.
(Source: BMJ Comments)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
(Source: BMJ Comments)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
The New River is filled with sewage and toxic pollution. Despite more than $90 million spent, the Mexican and U.S. governments have failed to clean it up.
The New River is filled with sewage and toxic pollution. Despite more than $90 million spent, the Mexican and U.S. governments have failed to clean it up.
ConclusionThe optimal dose of the JC pollen SLIT tablet was 5,000 JAU, with good efficacy and safety over a 3-year treatment period. This sustained effect was dependent on treatment duration. (Source: The Journal of Allergy and Clinical Immunology: In Practice)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2RObmqA
ConclusionModerate-to-severe AD is associated with significant decrements of health utility in the US population. These data illustrate the heavy societal burden of moderate and severe AD and provide important insight for prioritization of resource allocation and cost-effectiveness research. (Source: The Journal of Allergy and Clinical Immunology: In Practice)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Publication date: Available online 8 December 2018Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Mark Ballow, Tiffany Henderson, Christopher Scalchunes, R. Michael Blaese (Source: The Journal of Allergy and Clinical Immunology: In Practice)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Qp5hEv
ConclusionThe optimal dose of the JC pollen SLIT tablet was 5,000 JAU, with good efficacy and safety over a 3-year treatment period. This sustained effect was dependent on treatment duration. (Source: The Journal of Allergy and Clinical Immunology: In Practice)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2RObmqA
ConclusionModerate-to-severe AD is associated with significant decrements of health utility in the US population. These data illustrate the heavy societal burden of moderate and severe AD and provide important insight for prioritization of resource allocation and cost-effectiveness research. (Source: The Journal of Allergy and Clinical Immunology: In Practice)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Publication date: Available online 8 December 2018Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Mark Ballow, Tiffany Henderson, Christopher Scalchunes, R. Michael Blaese (Source: The Journal of Allergy and Clinical Immunology: In Practice)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Qp5hEv
Independent Research set a €100.00 ($116.28) price objective on Merck KGaA (FRA:MRK) in a research report report published on Thursday, November 15th.
Moon Fahel from San Antonio, Texas, had just gotten home from a martial arts class that he's been taking for the last 15 years when he answered the phone call ...
Independent Research set a €100.00 ($116.28) price objective on Merck KGaA (FRA:MRK) in a research report report published on Thursday, November 15th.
Moon Fahel from San Antonio, Texas, had just gotten home from a martial arts class that he's been taking for the last 15 years when he answered the phone call ...
Publication date: Available online 8 December 2018
Source: Auris Nasus Larynx
Author(s): Akiko Inoue, Shintaro Chiba, Kentaro Matsuura, Hiroshi Osafune, Robson Capasso, Kota Wada
Continuous positive airway pressure (CPAP) is the mainstay therapy for patients with obstructive sleep apnea (OSA) however compliance with CPAP is variable. Nasal ailments, such as nasal congestion are frequently mentioned as a cause for CPAP non-compliance, and potentially could be addressed prior to CPAP initiation, however, no specific criteria or recommendations for the evaluation and management of these patients exist. The aim of this retrospective study is to evaluate the effects of nasal anatomic features and disease on adherence to CPAP therapy for patients with OSA and determine the indications for pre-CPAP nasal treatment by using data obtained at clinical examination.
In total, 711 adult patients with initial diagnosis of OSA and an apnea–hypopnea index of ≥20 who were amenable to CPAP were included. We analyzed nasal parameters, past history of nasal disease, subjective symptoms, and disease severity in addition to whether CPAP therapy had been initiated, rate of CPAP therapy use (initial and 1 year), treatment continuation rate at 2 months and 1 year, and nasal treatments for all patients.
CPAP therapy was initiated in 543 of 711 patients. Nasal resistance was significantly higher in patients who discontinued therapy soon after CPAP initiation. Nasal disease and nasal parameters were not found to be predictors of treatment adherence at 1 year.
Allergic rhinitis, moderate to severe nasal congestion at bedtime, slight or extensive sinus opacification, and a high nasal septum deviation score were found to be independent predictors of nasal treatment, while strong awareness of nasal congestion, a past history of sinusitis, and a total nasal resistance (supine position) of ≥0.35 Pa/cm3/s were independent predictors of surgical treatment.
Long-term CPAP therapy adherence in patients with OSA can be predicted from initial CPAP adherence. Nasal disease and nasal parameters are important factors for early CPAP therapy discontinuation and should be adequately treated before therapy initiation to ensure long-term adherence. Indications for pre-CPAP nasal treatment and nasal surgery for patients with OSA can be predicted from the data obtained at the first examination, and these patients should be treated differently from those without OSA.
Publication date: Available online 8 December 2018
Source: Auris Nasus Larynx
Author(s): Akiko Inoue, Shintaro Chiba, Kentaro Matsuura, Hiroshi Osafune, Robson Capasso, Kota Wada
Continuous positive airway pressure (CPAP) is the mainstay therapy for patients with obstructive sleep apnea (OSA) however compliance with CPAP is variable. Nasal ailments, such as nasal congestion are frequently mentioned as a cause for CPAP non-compliance, and potentially could be addressed prior to CPAP initiation, however, no specific criteria or recommendations for the evaluation and management of these patients exist. The aim of this retrospective study is to evaluate the effects of nasal anatomic features and disease on adherence to CPAP therapy for patients with OSA and determine the indications for pre-CPAP nasal treatment by using data obtained at clinical examination.
In total, 711 adult patients with initial diagnosis of OSA and an apnea–hypopnea index of ≥20 who were amenable to CPAP were included. We analyzed nasal parameters, past history of nasal disease, subjective symptoms, and disease severity in addition to whether CPAP therapy had been initiated, rate of CPAP therapy use (initial and 1 year), treatment continuation rate at 2 months and 1 year, and nasal treatments for all patients.
CPAP therapy was initiated in 543 of 711 patients. Nasal resistance was significantly higher in patients who discontinued therapy soon after CPAP initiation. Nasal disease and nasal parameters were not found to be predictors of treatment adherence at 1 year.
Allergic rhinitis, moderate to severe nasal congestion at bedtime, slight or extensive sinus opacification, and a high nasal septum deviation score were found to be independent predictors of nasal treatment, while strong awareness of nasal congestion, a past history of sinusitis, and a total nasal resistance (supine position) of ≥0.35 Pa/cm3/s were independent predictors of surgical treatment.
Long-term CPAP therapy adherence in patients with OSA can be predicted from initial CPAP adherence. Nasal disease and nasal parameters are important factors for early CPAP therapy discontinuation and should be adequately treated before therapy initiation to ensure long-term adherence. Indications for pre-CPAP nasal treatment and nasal surgery for patients with OSA can be predicted from the data obtained at the first examination, and these patients should be treated differently from those without OSA.

Thyroid disorders are believed to affect around one in 20 people in the UK, yet because the symptoms – such as weight changes, depression and fatigue – can ...

Thyroid disorders are believed to affect around one in 20 people in the UK, yet because the symptoms – such as weight changes, depression and fatigue – can ...
Publication date: February 2019
Source: Journal of Environmental Radioactivity, Volume 197
Author(s): J. Kastlander, M. Aldener, T. Fritioff, L. Raghoo, R. Purtschert
Among the most important indicators for an underground nuclear explosion are the radioactive xenon isotopes 131mXe, 133Xe, 133mXe and 135Xe and the radioactive argon isotope 37Ar. In order to evaluate a detection of these nuclides in the context of a nuclear test verification regime it is crucial to have knowledge about expected background concentrations. Sub soil gas sampling was carried out on the oil shale ash waste pile in Kvarntorp, Sweden, a location with known elevated uranium content where 133Xe and 37Ar were detected in concentrations up to 120 mBq/m3 and 40 mBq/m3 respectively. These data provides one of the first times when xenon and argon were both detected in the same sub soil gas. This, and the correlations between the radionuclides, the sub soil gas contents (i.e. CO2, O2, and radon) and uranium concentration in the pile, provide very interesting information regarding the natural background and the xenon concentration levels and can most likely be used as an upper limit on what to be expected naturally occurring.
Publication date: February 2019
Source: Journal of Environmental Radioactivity, Volume 197
Author(s): J. Kastlander, M. Aldener, T. Fritioff, L. Raghoo, R. Purtschert
Among the most important indicators for an underground nuclear explosion are the radioactive xenon isotopes 131mXe, 133Xe, 133mXe and 135Xe and the radioactive argon isotope 37Ar. In order to evaluate a detection of these nuclides in the context of a nuclear test verification regime it is crucial to have knowledge about expected background concentrations. Sub soil gas sampling was carried out on the oil shale ash waste pile in Kvarntorp, Sweden, a location with known elevated uranium content where 133Xe and 37Ar were detected in concentrations up to 120 mBq/m3 and 40 mBq/m3 respectively. These data provides one of the first times when xenon and argon were both detected in the same sub soil gas. This, and the correlations between the radionuclides, the sub soil gas contents (i.e. CO2, O2, and radon) and uranium concentration in the pile, provide very interesting information regarding the natural background and the xenon concentration levels and can most likely be used as an upper limit on what to be expected naturally occurring.
Iodine-131 is critical radioisotope for diagnoses and treatment of thyroid cancer and hyperthyroidism.
![]()
Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 11759 shares of the business's stock in a transaction on Wednesday, November 28th. The shares ...
Iodine-131 is critical radioisotope for diagnoses and treatment of thyroid cancer and hyperthyroidism.
![]()
Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 11759 shares of the business's stock in a transaction on Wednesday, November 28th. The shares ...
Updated Date: Dec 7, 2018 EST (Source: DailyMed Drug Label Updates)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Updated Date: Dec 7, 2018 EST (Source: DailyMed Drug Label Updates)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EbaaJK
Updated Date: Dec 7, 2018 EST (Source: DailyMed Drug Label Updates)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EbaaJK
Updated Date: Dec 7, 2018 EST (Source: DailyMed Drug Label Updates)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
+ Author Affiliations. 1Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania. 2Department of Radiology, University of Pittsburgh, ...
+ Author Affiliations. 1Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania. 2Department of Radiology, University of Pittsburgh, ...
Publication date: Available online 8 December 2018
Source: European Journal of Radiology
Author(s): Andrew D. Choi, Eric S. Leifer, Jeannie Yu, Tanuka Datta, Kathie Bronson, Shirley Rollison, John Schuzer, Chloe Steveson, Sujata M. Shanbhag, Marcus Y. Chen
Assessing coronary artery calcium (CAC) is a valuable tool for individualizing cardiac risk assessment. In CAC scanning, this technical report assesses the use of a true model-based iterative reconstruction algorithm using forward projected model-based iterative reconstruction ("FIRST") and assess whether FIRST allows for reduced radiation dose CAC scanning on 320-detector row computed tomography (320-CT). Here, 100 consecutive patients prospectively underwent reduced and standard dose scans. For the patients (59 ± 9 years, 61% male) stratified by Agatston categories 0, 1-10, 11-100, 101-400,> 400, agreement between reduced dose with FIRST versus standard dose with FBP was excellent at 81% (95% CI: 73-88%) with kappa 0.74 (95% CI: 0.64–0.85). Median radiation exposure was 75% lower for reduced (0.35 mSv) versus standard dose (1.37 mSv) scans. In conclusion, agreement was excellent for reduced dose with FIRST and standard dose with FBP in 320-detector row CT CAC imaging in well-established categories of cardiovascular risk. These methods make it possible to reduce radiation exposure by 75%.
Publication date: Available online 8 December 2018
Source: European Journal of Radiology
Author(s): Andrew D. Choi, Eric S. Leifer, Jeannie Yu, Tanuka Datta, Kathie Bronson, Shirley Rollison, John Schuzer, Chloe Steveson, Sujata M. Shanbhag, Marcus Y. Chen
Assessing coronary artery calcium (CAC) is a valuable tool for individualizing cardiac risk assessment. In CAC scanning, this technical report assesses the use of a true model-based iterative reconstruction algorithm using forward projected model-based iterative reconstruction ("FIRST") and assess whether FIRST allows for reduced radiation dose CAC scanning on 320-detector row computed tomography (320-CT). Here, 100 consecutive patients prospectively underwent reduced and standard dose scans. For the patients (59 ± 9 years, 61% male) stratified by Agatston categories 0, 1-10, 11-100, 101-400,> 400, agreement between reduced dose with FIRST versus standard dose with FBP was excellent at 81% (95% CI: 73-88%) with kappa 0.74 (95% CI: 0.64–0.85). Median radiation exposure was 75% lower for reduced (0.35 mSv) versus standard dose (1.37 mSv) scans. In conclusion, agreement was excellent for reduced dose with FIRST and standard dose with FBP in 320-detector row CT CAC imaging in well-established categories of cardiovascular risk. These methods make it possible to reduce radiation exposure by 75%.
Publication date: Available online 8 December 2018
Source: Journal of Forensic Radiology and Imaging
Author(s): Masanori Ishida, Wataru Gonoi, Go Shirota, Hidemi Okuma, Sho Yamazawa, Munetoshi Hinata, Akimasa Hayashi, Masashi Fukayama, Osamu Abe
We present two cases of diffusely decreased liver attenuation on post-mortem computed tomography (CT) which is lower than that on ante-mortem CT. Cases include a 37-year-old female whose cause of death was related to myelodysplastic syndrome (Case #1) and an 88-year-old female whose cause of death was related to malignant lymphoma (Case #2). We compared post-mortem CT (PMCT) liver attenuations with those on ante-mortem CT (AMCT). For Case #1, average AMCT values of the right/left liver were 46.1/50.0 Hounsfield Units (HU) 2 days ante-mortem and PMCT values of the right/left liver were 33.9/38.4 HU 3 hours post-mortem. For Case #2, average AMCT values were 61.4/54.9 HU 5 days ante-mortem and PMCT values of the right/left liver were 38.2/40.6 HU 2 hours post-mortem. In both Case # 1 and #2, decreased liver attenuations were found on PMCT. Further, autopsy revealed diffuse hepatocellular hemorrhage, deficits, and necrosis in Case #1, and liver infiltration of lymphoma in Case #2. These pathological findings were considered to be related to diffusely decreased liver attenuation on PMCT in conjunction with remarkable deterioration of hepatobiliary function before death. The observed decreases in liver attenuation on PMCT may be attributed mainly to hepatic pathological changes just prior to death. PMCT liver attenuation does not necessarily reflect the ante-mortem state some time before death, and it is therefore necessary to be careful when presuming the ante-mortem hepatic pathological conditions from only PMCT. This attenuation change should be taken into account during PMCT interpretation.
Publication date: Available online 8 December 2018
Source: Journal of Forensic Radiology and Imaging
Author(s): Masanori Ishida, Wataru Gonoi, Go Shirota, Hidemi Okuma, Sho Yamazawa, Munetoshi Hinata, Akimasa Hayashi, Masashi Fukayama, Osamu Abe
We present two cases of diffusely decreased liver attenuation on post-mortem computed tomography (CT) which is lower than that on ante-mortem CT. Cases include a 37-year-old female whose cause of death was related to myelodysplastic syndrome (Case #1) and an 88-year-old female whose cause of death was related to malignant lymphoma (Case #2). We compared post-mortem CT (PMCT) liver attenuations with those on ante-mortem CT (AMCT). For Case #1, average AMCT values of the right/left liver were 46.1/50.0 Hounsfield Units (HU) 2 days ante-mortem and PMCT values of the right/left liver were 33.9/38.4 HU 3 hours post-mortem. For Case #2, average AMCT values were 61.4/54.9 HU 5 days ante-mortem and PMCT values of the right/left liver were 38.2/40.6 HU 2 hours post-mortem. In both Case # 1 and #2, decreased liver attenuations were found on PMCT. Further, autopsy revealed diffuse hepatocellular hemorrhage, deficits, and necrosis in Case #1, and liver infiltration of lymphoma in Case #2. These pathological findings were considered to be related to diffusely decreased liver attenuation on PMCT in conjunction with remarkable deterioration of hepatobiliary function before death. The observed decreases in liver attenuation on PMCT may be attributed mainly to hepatic pathological changes just prior to death. PMCT liver attenuation does not necessarily reflect the ante-mortem state some time before death, and it is therefore necessary to be careful when presuming the ante-mortem hepatic pathological conditions from only PMCT. This attenuation change should be taken into account during PMCT interpretation.
Publication date: Available online 8 December 2018
Source: The Journal of Allergy and Clinical Immunology: In Practice
Author(s): Minoru Gotoh, Syuji Yonekura, Toru Imai, Shinya Kaneko, Eiji Horikawa, Akiyoshi Konno, Yoshitaka Okamoto, Kimihiro Okubo
Japanese cedar (JC) pollinosis is a common allergic rhinitis in Japan. The JC pollen SLIT tablet was developed using the highest concentration of JC pollen extract.
This was a randomized, double-blind, placebo-controlled phase II/III trial to investigate the optimal dose of the JC pollen SLIT tablet and examine long-term efficacy and safety for 3 years with the selected dose, and 2-year follow-up.
A total 1,042 patients with JC pollinosis (aged 5–64 years) were equally randomized into four groups and received daily treatment with 2,000, 5,000, or 10,000 Japanese allergy unit (JAU) or placebo. The primary endpoint was the total nasal symptom and medication score (TNSMS) during the peak symptom period in the first season. Key secondary endpoints were TNSMS for the JC pollen dispersion season and total nasal and ocular symptom and medication score (TNOSMS) for the peak symptom period and JC pollen dispersion season.
For the primary endpoint, absolute reductions and relative mean reductions in TNSMS compared with placebo were 1.50 and 21.4%, 2.24 and 32.1%, and 2.18 and 31.2% for 2,000, 5,000, and 10,000 JAU, respectively (P < .001 in all groups). For all key secondary endpoints, efficacy was confirmed for all doses (P < .001 in all groups). The treatment was well tolerated. Long-term efficacy of 5,000 JAU was shown over the 3 years.
The optimal dose of the JC pollen SLIT tablet was 5,000 JAU, with good efficacy and safety over a 3-year treatment period. This sustained effect was dependent on treatment duration.
Publication date: Available online 8 December 2018
Source: The Journal of Allergy and Clinical Immunology: In Practice
Author(s): Mark Ballow, Tiffany Henderson, Christopher Scalchunes, R. Michael Blaese
Publication date: Available online 8 December 2018
Source: The Journal of Allergy and Clinical Immunology: In Practice
Author(s): Jonathan I. Silverberg, Joel M. Gelfand, David J. Margolis, Mark Boguniewicz, Luz Fonacier, Mitchell H. Grayson, Peck Y. Ong, Zelma Chiesa Fuxench, Eric L. Simpson
The impact of atopic dermatitis (AD) on health related quality of life and health utility in the United States adult population is not well-established.
To determine the health utilities and quality of life adjusted years (QALYs) lost in adults with vs. without AD among the US population.
A cross-sectional, population-based study of 3,495 adults was performed. AD was determined using modified UK Diagnostic Criteria for AD. AD severity was assessed using self-reported global AD severity, Patient-Oriented Eczema Measure (POEM), Patient-Oriented Scoring AD (PO-SCORAD), PO-SCORAD-itch and sleep. SF-6D health utility scores and total QALY loss were assessed.
The mean [95% confidence interval] SF-6D score was lower in adults with AD compared to healthy adults (0.69 [0.68-0.70] vs. 0.79 [0.77-0.79]). In particular, moderate-severe AD (mean: 0.53-0.66) had similar or lower SF-6D scores than all other self-reported disorders examined, except autoimmune disorders. Adults with AD and atopic comorbidities had significantly lower SF-6D scores compared to those without atopic comorbidities. Among the 7 disorders examined, AD was associated with higher total QALY loss than autoimmune disorders, diabetes, food allergy, and heart disease in both males and females. The largest QALY loss was for moderate AD in females and mild AD in males.
Moderate-to-severe AD is associated with significant decrements of health utility in the US population. These data illustrate the heavy societal burden of moderate and severe AD and provide important insight for prioritization of resource allocation and cost-effectiveness research.
Publication date: Available online 8 December 2018
Source: The Journal of Allergy and Clinical Immunology: In Practice
Author(s): Minoru Gotoh, Syuji Yonekura, Toru Imai, Shinya Kaneko, Eiji Horikawa, Akiyoshi Konno, Yoshitaka Okamoto, Kimihiro Okubo
Japanese cedar (JC) pollinosis is a common allergic rhinitis in Japan. The JC pollen SLIT tablet was developed using the highest concentration of JC pollen extract.
This was a randomized, double-blind, placebo-controlled phase II/III trial to investigate the optimal dose of the JC pollen SLIT tablet and examine long-term efficacy and safety for 3 years with the selected dose, and 2-year follow-up.
A total 1,042 patients with JC pollinosis (aged 5–64 years) were equally randomized into four groups and received daily treatment with 2,000, 5,000, or 10,000 Japanese allergy unit (JAU) or placebo. The primary endpoint was the total nasal symptom and medication score (TNSMS) during the peak symptom period in the first season. Key secondary endpoints were TNSMS for the JC pollen dispersion season and total nasal and ocular symptom and medication score (TNOSMS) for the peak symptom period and JC pollen dispersion season.
For the primary endpoint, absolute reductions and relative mean reductions in TNSMS compared with placebo were 1.50 and 21.4%, 2.24 and 32.1%, and 2.18 and 31.2% for 2,000, 5,000, and 10,000 JAU, respectively (P < .001 in all groups). For all key secondary endpoints, efficacy was confirmed for all doses (P < .001 in all groups). The treatment was well tolerated. Long-term efficacy of 5,000 JAU was shown over the 3 years.
The optimal dose of the JC pollen SLIT tablet was 5,000 JAU, with good efficacy and safety over a 3-year treatment period. This sustained effect was dependent on treatment duration.
Publication date: Available online 8 December 2018
Source: The Journal of Allergy and Clinical Immunology: In Practice
Author(s): Mark Ballow, Tiffany Henderson, Christopher Scalchunes, R. Michael Blaese
Publication date: Available online 8 December 2018
Source: The Journal of Allergy and Clinical Immunology: In Practice
Author(s): Jonathan I. Silverberg, Joel M. Gelfand, David J. Margolis, Mark Boguniewicz, Luz Fonacier, Mitchell H. Grayson, Peck Y. Ong, Zelma Chiesa Fuxench, Eric L. Simpson
The impact of atopic dermatitis (AD) on health related quality of life and health utility in the United States adult population is not well-established.
To determine the health utilities and quality of life adjusted years (QALYs) lost in adults with vs. without AD among the US population.
A cross-sectional, population-based study of 3,495 adults was performed. AD was determined using modified UK Diagnostic Criteria for AD. AD severity was assessed using self-reported global AD severity, Patient-Oriented Eczema Measure (POEM), Patient-Oriented Scoring AD (PO-SCORAD), PO-SCORAD-itch and sleep. SF-6D health utility scores and total QALY loss were assessed.
The mean [95% confidence interval] SF-6D score was lower in adults with AD compared to healthy adults (0.69 [0.68-0.70] vs. 0.79 [0.77-0.79]). In particular, moderate-severe AD (mean: 0.53-0.66) had similar or lower SF-6D scores than all other self-reported disorders examined, except autoimmune disorders. Adults with AD and atopic comorbidities had significantly lower SF-6D scores compared to those without atopic comorbidities. Among the 7 disorders examined, AD was associated with higher total QALY loss than autoimmune disorders, diabetes, food allergy, and heart disease in both males and females. The largest QALY loss was for moderate AD in females and mild AD in males.
Moderate-to-severe AD is associated with significant decrements of health utility in the US population. These data illustrate the heavy societal burden of moderate and severe AD and provide important insight for prioritization of resource allocation and cost-effectiveness research.
Cancer Network speaks with Dr. Leon Ptaszek about managing cancer patients who have atrial fibrillation and are being treated with BTK inhibitors.
KINGSPORT, Tenn., Nov. 26, 2018 (GLOBE NEWSWIRE) -- ITL Pharma, Inc. (ITL), a LIAS Company, today announced awarding of a United States Patent ...
KINGSPORT, Tenn., Nov. 26, 2018 (GLOBE NEWSWIRE) -- ITL Pharma, Inc. (ITL), a LIAS Company, today announced awarding of a United States Patent ...
Cancer Network speaks with Dr. Leon Ptaszek about managing cancer patients who have atrial fibrillation and are being treated with BTK inhibitors.

The objective of Thyroid Cancer Treatment Market Industry report is to enlighten the users with the crucial aspects of Global Thyroid Cancer Treatment Market ...
Publication date: Available online 8 December 2018
Source: NeuroImage
Author(s): M. Catalina Camacho, Helmet T. Karim, Susan B. Perlman
Adaptive emotion processing is critical for nearly all aspects of social and emotional functioning. There are distinct developmental trajectories associated with improved emotion processing, with a protracted developmental course for negative or complex emotions. The specific changes in neural circuitry that underlie this development, however are still scarcely understood. We employed a multivariate approach in order to elucidate distinctions in complex, naturalistic emotion processing between childhood and adulthood.
Twenty-one adults (M±SD age = 26.57 ± 5.08 years) and thirty children (age = 7.75 ± 1.80 years) completed a free-viewing movie task during BOLD fMRI scanning. This task was designed to assess naturalistic processing of movie clips portraying positive, negative, and neutral emotions. Multivariate support vector machines (SVM) were trained to classify age groups based on neural activation during the task.
SVMs were able to successfully classify condition (positive, negative, and neutral) across all participants with high accuracy (61.44%). SVMs could successfully distinguish adults and children within each condition (ps < 0.05). Regions that informed the age group SVMs were associated with sensory and socio-emotional processing (inferior parietal lobule), emotion regulation (inferior frontal gyrus), and sensory regions of the temporal and occipital lobes.
These results point to distributed differences in activation between childhood and adulthood unique to each emotional condition. In the negative condition specifically, there is evidence for a shift in engagement from regions of sensory and socio-emotional integration to emotion regulation regions between children and adults. These results provide insight into circuitry contributing to maturation of emotional processing across development.
Publication date: Available online 8 December 2018
Source: NeuroImage
Author(s): Esther H.H. Keulers, María Björk Birkisdóttir, Luciana Falbo, Anique de Bruin, Peter L.J. Stiers
Adolescence is associated with widespread maturation of brain structures and functional connectivity profiles that shift from local to more distributed and better integrated networks, which are active during a variety of cognitive tasks. Nevertheless, the approach to examine task-induced developmental brain changes is function-specific, leaving the question open whether functional maturation is specific to the particular cognitive demands of the task used, or generalizes across different tasks. In the present study we examine the hypothesis that functional brain maturation is driven by global changes in how the brain handles cognitive demands. Multivariate pattern classification analysis (MVPA) was used to examine whether age discriminative task-induced activation patterns generalize across a wide range of information processing levels. 25 young (13-years old) and 22 old (17-years old) adolescents performed three conceptually different tasks of metacognition, cognition and visual processing. MVPA applied within each task indicated that task-induced brain activation is consistent and reliably different between ages 13 and 17. These age-discriminative activation patterns proved to be common across the different tasks used, despite the differences in cognitive demands and brain structures engaged by each of the three tasks. MVP classifiers trained to detect age-discriminative patterns in brain activation during one task were significantly able to decode age from brain activation maps during execution of other tasks with accuracies between 63 and 75%. The results emphasize that age-specific characteristics of task-induced brain activation have to be understood at the level of brain-wide networks that show maturational changes in their organization and processing efficacy during adolescence.
Publication date: Available online 8 December 2018
Source: NeuroImage
Author(s): Esther H.H. Keulers, María Björk Birkisdóttir, Luciana Falbo, Anique de Bruin, Peter L.J. Stiers
Adolescence is associated with widespread maturation of brain structures and functional connectivity profiles that shift from local to more distributed and better integrated networks, which are active during a variety of cognitive tasks. Nevertheless, the approach to examine task-induced developmental brain changes is function-specific, leaving the question open whether functional maturation is specific to the particular cognitive demands of the task used, or generalizes across different tasks. In the present study we examine the hypothesis that functional brain maturation is driven by global changes in how the brain handles cognitive demands. Multivariate pattern classification analysis (MVPA) was used to examine whether age discriminative task-induced activation patterns generalize across a wide range of information processing levels. 25 young (13-years old) and 22 old (17-years old) adolescents performed three conceptually different tasks of metacognition, cognition and visual processing. MVPA applied within each task indicated that task-induced brain activation is consistent and reliably different between ages 13 and 17. These age-discriminative activation patterns proved to be common across the different tasks used, despite the differences in cognitive demands and brain structures engaged by each of the three tasks. MVP classifiers trained to detect age-discriminative patterns in brain activation during one task were significantly able to decode age from brain activation maps during execution of other tasks with accuracies between 63 and 75%. The results emphasize that age-specific characteristics of task-induced brain activation have to be understood at the level of brain-wide networks that show maturational changes in their organization and processing efficacy during adolescence.
Publication date: Available online 8 December 2018
Source: NeuroImage
Author(s): M. Catalina Camacho, Helmet T. Karim, Susan B. Perlman
Adaptive emotion processing is critical for nearly all aspects of social and emotional functioning. There are distinct developmental trajectories associated with improved emotion processing, with a protracted developmental course for negative or complex emotions. The specific changes in neural circuitry that underlie this development, however are still scarcely understood. We employed a multivariate approach in order to elucidate distinctions in complex, naturalistic emotion processing between childhood and adulthood.
Twenty-one adults (M±SD age = 26.57 ± 5.08 years) and thirty children (age = 7.75 ± 1.80 years) completed a free-viewing movie task during BOLD fMRI scanning. This task was designed to assess naturalistic processing of movie clips portraying positive, negative, and neutral emotions. Multivariate support vector machines (SVM) were trained to classify age groups based on neural activation during the task.
SVMs were able to successfully classify condition (positive, negative, and neutral) across all participants with high accuracy (61.44%). SVMs could successfully distinguish adults and children within each condition (ps < 0.05). Regions that informed the age group SVMs were associated with sensory and socio-emotional processing (inferior parietal lobule), emotion regulation (inferior frontal gyrus), and sensory regions of the temporal and occipital lobes.
These results point to distributed differences in activation between childhood and adulthood unique to each emotional condition. In the negative condition specifically, there is evidence for a shift in engagement from regions of sensory and socio-emotional integration to emotion regulation regions between children and adults. These results provide insight into circuitry contributing to maturation of emotional processing across development.
Publication date: Available online 8 December 2018
Source: Journal of Allergy and Clinical Immunology
Author(s): Michelle Daya, Kathleen C. Barnes
Publication date: Available online 8 December 2018
Source: Journal of Allergy and Clinical Immunology
Author(s): Cindy L.J. Weinstein, Nicholas Ryan, Tulin Shekar, Davis Gates, Stephen J. Lane, Ioana Agache, Robert A. Nathan, SPIRO Investigators
The safety of long-acting beta agonists added to inhaled corticosteroids for the treatment of persistent asthma has been controversial.
To determine whether administering formoterol in combination with mometasone furoate increases the risk of serious asthma outcomes compared to mometasone furoate alone.
We conducted a 26-week, randomized, double-blind trial in adolescent and adult patients (≥12 years) with persistent asthma in 35 countries with the primary objective of evaluating whether mometasone furoate-formoterol increases the risk of serious asthma outcomes (adjudicated hospitalization, intubation, or death) compared to mometasone furoate alone. The key efficacy endpoint was asthma exacerbation (composite of hospitalizations ≥24 h, emergency visits <24 h requiring systemic corticosteroid, or systemic corticosteroid for ≥3 consecutive days).
Among 11,729 patients (mometasone furoate-formoterol, n=5868; mometasone furoate, n=5861), a total of 81 serious asthma outcomes, all asthma-related hospitalizations, were observed in 71 patients; 45 events from 39 patients on mometasone furoate-formoterol and 36 events from 32 patients on mometasone furoate. The hazard ratio for the first serious asthma outcome in the mometasone furoate-formoterol versus mometasone furoate group was 1.22 (95% CI: 0.76 to 1.94, p=0.411). Asthma exacerbation occurred in 1487 patients; 708 on mometasone furoate-formoterol and 779 on mometasone furoate. The hazard ratio for the first asthma exacerbation in the mometasone furoate-formoterol versus mometasone furoate group was 0.89 (95% CI: 0.80 to 0.98, p=0.021).
The addition of formoterol to mometasone maintenance therapy did not increase the risk of serious asthma-related events and reduced the risk of asthma exacerbation.
Publication date: Available online 8 December 2018
Source: Journal of Allergy and Clinical Immunology
Author(s): Michelle Daya, Kathleen C. Barnes
Publication date: Available online 8 December 2018
Source: Journal of Allergy and Clinical Immunology
Author(s): Cindy L.J. Weinstein, Nicholas Ryan, Tulin Shekar, Davis Gates, Stephen J. Lane, Ioana Agache, Robert A. Nathan, SPIRO Investigators
The safety of long-acting beta agonists added to inhaled corticosteroids for the treatment of persistent asthma has been controversial.
To determine whether administering formoterol in combination with mometasone furoate increases the risk of serious asthma outcomes compared to mometasone furoate alone.
We conducted a 26-week, randomized, double-blind trial in adolescent and adult patients (≥12 years) with persistent asthma in 35 countries with the primary objective of evaluating whether mometasone furoate-formoterol increases the risk of serious asthma outcomes (adjudicated hospitalization, intubation, or death) compared to mometasone furoate alone. The key efficacy endpoint was asthma exacerbation (composite of hospitalizations ≥24 h, emergency visits <24 h requiring systemic corticosteroid, or systemic corticosteroid for ≥3 consecutive days).
Among 11,729 patients (mometasone furoate-formoterol, n=5868; mometasone furoate, n=5861), a total of 81 serious asthma outcomes, all asthma-related hospitalizations, were observed in 71 patients; 45 events from 39 patients on mometasone furoate-formoterol and 36 events from 32 patients on mometasone furoate. The hazard ratio for the first serious asthma outcome in the mometasone furoate-formoterol versus mometasone furoate group was 1.22 (95% CI: 0.76 to 1.94, p=0.411). Asthma exacerbation occurred in 1487 patients; 708 on mometasone furoate-formoterol and 779 on mometasone furoate. The hazard ratio for the first asthma exacerbation in the mometasone furoate-formoterol versus mometasone furoate group was 0.89 (95% CI: 0.80 to 0.98, p=0.021).
The addition of formoterol to mometasone maintenance therapy did not increase the risk of serious asthma-related events and reduced the risk of asthma exacerbation.
![]()
Shares of Interpace Diagnostics Group Inc (NASDAQ:IDXG) have been assigned an average rating of "Buy" from the seven ratings firms that are currently ...
![]()
Veracyte (NASDAQ:VCYT) and Guardant Health (NASDAQ:GH) are both medical companies, but which is the superior business? We will compare the two ...
![]()
Veracyte (NASDAQ:VCYT) and Guardant Health (NASDAQ:GH) are both medical companies, but which is the superior business? We will compare the two ...
![]()
Shares of Interpace Diagnostics Group Inc (NASDAQ:IDXG) have been assigned an average rating of "Buy" from the seven ratings firms that are currently ...
Condition: HIV Infections Interventions: Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets; Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release) Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); International Maternal Pediatric Adolescent AIDS Clinical Trials Network; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH); ViiV Hea lthcare Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2BYsjci
Condition: Pneumonia Childhood Intervention: Behavioral: Decision Support Sponsors: Vanderbilt University Medical Center; National Institute of Allergy and Infectious Diseases (NIAID); University of Utah; Intermountain Health Care, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
Conditions: Rhinitis, Allergic; Rhinoconjunctivitis, Allergic Intervention: Biological: HAL-MRE1 Sponsor: HAL Allergy Not yet recruiting (Source: ClinicalTrials.gov)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2C09w0n
Condition: Penicillin Allergy Intervention: Diagnostic Test: Penicillin Skin Testing Sponsor: CHU de Quebec-Universite Laval Not yet recruiting (Source: ClinicalTrials.gov)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2L52Vok
Condition: Penicillin Allergy Intervention: Diagnostic Test: Penicillin Skin Testing Sponsor: CHU de Quebec-Universite Laval Not yet recruiting (Source: ClinicalTrials.gov)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2L52Vok
Condition: HIV Infections Interventions: Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets; Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release) Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); International Maternal Pediatric Adolescent AIDS Clinical Trials Network; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH); ViiV Hea lthcare Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2BYsjci
Condition: Pneumonia Childhood Intervention: Behavioral: Decision Support Sponsors: Vanderbilt University Medical Center; National Institute of Allergy and Infectious Diseases (NIAID); University of Utah; Intermountain Health Care, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
Conditions: Rhinitis, Allergic; Rhinoconjunctivitis, Allergic Intervention: Biological: HAL-MRE1 Sponsor: HAL Allergy Not yet recruiting (Source: ClinicalTrials.gov)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2C09w0n
![]()
WINTON GROUP Ltd lessened its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 44.4% during the 3rd quarter, according to the company in its most ...
![]()
WINTON GROUP Ltd lessened its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 44.4% during the 3rd quarter, according to the company in its most ...